التفاصيل البيبلوغرافية
| العنوان: |
Results of haploidentical transplant in patients with donor-specific antibodies : a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy |
| المؤلفون: |
Bailén, Rebeca, Alenda, Raquel, Herruzo-Delgado, Beatriz, Acosta-Fleitas, Cynthia, Vallés, Ana, Esquirol, Albert, Fonseca, Marta, Solán, Laura, Sánchez-Vadillo, Irene, Bautista, Guiomar, Bento, Leyre, López-Godino, Oriana, Pérez-Martínez, Ariadna, Torrent Catarineu, Anna, Zanabili, Joud, Calbacho, Maria, Moreno, Miguel Ángel, Pascual-Cascón, María Jesús, Guerra-Domínguez, Luisa, Chinea, Anabelle, Garcia Cadenas, Irene, López-Corral, Lucía, Boix, Francisco, López Lorenzo, José Luis, Humala, Karem, Duarte, Rafael, Sampol, Antonia, Heras, Inmaculada, Vicario, José Luis, Balas, Antonio, Oarbeascoa, Gillen, Fernández-Caldas, Paula, Anguita, Javier, Kwon, Mi, Universitat Autònoma de Barcelona |
| سنة النشر: |
2023 |
| المجموعة: |
Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB |
| مصطلحات موضوعية: |
DSA kinetics, Desensitization strategies, Donor-specific antibodies, Graft failure, Haplo-hsct |
| الوصف: |
Donor-specific antibodies (DSAs) are IgG allo-antibodies against mismatched donor HLA molecules and can cause graft failure (GF) in the setting of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Our aim was to report the experience of the Spanish Group of Hematopoietic Transplant (GETH-TC) in DSA-positive patients who had undergone haplo-HSCT. We conducted a survey of patients who underwent haplo-HSCT in GETH-TC centers between 2012 and 2021. Data were collected on the DSA assay used, monitoring strategy, complement fixation, criteria for desensitization, desensitization strategies and transplant outcomes. Fifteen centers from the GETH-TC responded to the survey. During the study period, 1,454 patients underwent haplo-HSCT. Seventy of the transplants were performed in 69 DSA-positive patients, all of whom lacked a suitable alternative donor; 61 (88%) patients were female (90% with prior pregnancies). All patients received post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Regarding baseline DSA intensity, 46 (67%) patients presented mean fluorescence intensity (MFI) >5,000, including 21 (30%) with MFI >10,000 and three (4%) with MFI >20,000. Six patients did not receive desensitization treatment, four of them with MFI <5,000. Of 63 patients receiving desensitization treatment, 48 (76%) were tested after desensitization therapy, and a reduction in intensity was confirmed in 45 (71%). Three patients (5%) experienced an increase in MFI after desensitization, two of whom experienced primary GF. Cumulative incidence of neutrophil engraftment at day 28 was 74% in a median of 18 days (IQR, 15─20); six patients died before engraftment due to toxicity or infection and eight patients had primary GF despite desensitization in seven of them. After a median follow-up of 30 months, two-year overall and event-free survival were 46.5% and 39%, respectively. The two-year cumulative incidence of relapse was 16% and non-relapse mortality (NRM) was 43%. Infection was the ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
Frontiers in immunology; Vol. 14 (may 2023); https://ddd.uab.cat/record/279352Test; urn:10.3389/fimmu.2023.1165759; urn:oai:ddd.uab.cat:279352; urn:pmcid:PMC10250708; urn:pmc-uid:10250708; urn:pmid:37304258; urn:oai:pubmedcentral.nih.gov:10250708 |
| الإتاحة: |
https://ddd.uab.cat/record/279352Test |
| حقوق: |
open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.9EA36153 |
| قاعدة البيانات: |
BASE |
